REACT-AF: The Rhythm Evaluation for AntiCoagulaTion with Continuous Monitoring of Atrial Fibrillation
REACT-AF: Evaluation of Blood-Thinning Medication in Patients with Atrial Fibrillation (AF)
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAU5833
U.S. Govt. ID: NCT05836987
Contact: Esteban Ceballos: / ec3539@cumc.columbia.edu
Additional Study Information: The purpose of this study is to assess whether it is safe and effective to stop oral anticoagulation medication (a blood-thinning medication) during prolonged periods of normal heart rhythm in participants with infrequent episodes of atrial fibrillation (AF). Atrial fibrillation (AF) is the most common abnormal heart rhythm and is associated with an increased risk of stroke, heart failure, and death.
Investigator
Angelo Biviano, MD, MPH
Do You Qualify?
Are you between the ages of 22-85? Yes No
Have you been diagnosed with Atrial Fibrillation (AF)? Yes No
Do you speak English? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Esteban Ceballos
ec3539@cumc.columbia.edu

This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE